financetom
Business
financetom
/
Business
/
Why Invo BioScience Stock Is Soaring Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Invo BioScience Stock Is Soaring Today
Apr 17, 2024 9:11 AM

INVO BioScience, Inc. ( INVO ) shares are trading higher Wednesday after the company reported its fourth-quarter financial results after the market close Tuesday. Here's a look at the details.

The Details:

Invo Bioscience ( INVO ) reported $1.38 million in quarterly sales, representing a 396.15% increase over sales of $278,140 from the same period last year.

The company also said it remains on-track with its goal of reaching break-even or profitability within its current operations in 2024. 

Invo BioScience ( INVO ) said it remains committed to acquire NAYA Biosciences in an all-stock transaction. Following the closing of the Merger, the combined company is expected to operate under the name “NAYA Biosciences.”

“We continue to execute on our plan to capture a greater share of the total fertility cycle revenue and profit through the transformation of INVO into an innovative healthcare services company, driven by our existing INVO Centers and recently acquired Wisconsin-based IVF Center,” commented Steve Shum, CEO of Invo.

Related News: What’s Going On With AMC Entertainment Stock?

INVO Stock Prediction 2024:

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at INVO Bioscience ( INVO ) , an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For INVO Bioscience ( INVO ), the 200-day moving average sits at $1.49, according to Benzinga Pro, which is below the current price of $2.59. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

INVO Price Action: According to Benzinga Pro, Invo BioScience ( INVO ) shares are up 264% at $2.77 at the time of publication Wednesday.

Image: PublicDomainPictures from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Fact Ii Acquisition Corp. Announces Pricing Of $175 Million Initial Public Offering
BRIEF-Fact Ii Acquisition Corp. Announces Pricing Of $175 Million Initial Public Offering
Nov 26, 2024
Nov 26 (Reuters) - FACT II Acquisition Corp: * FACT II ACQUISITION CORP. ANNOUNCES PRICING OF $175 MILLION INITIAL PUBLIC OFFERING * FACT II ACQUISITION CORP - PRICES IPO OF 17.5 MILLION UNITS AT $10.00 PER UNIT ...
Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ
Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ
Nov 26, 2024
12:27 PM EST, 11/26/2024 (MT Newswires) -- Valneva (VALN) said Tuesday it has submitted a label extension application to the US Food and Drug Administration to expand the use of its chikungunya virus vaccine IXCHIQ to individuals between 12 and 17 years old. The application also seeks to include two-year antibody persistence data on the product label, highlighting a key...
Aston Martin expects lower full-year core profit as delivery delays bite
Aston Martin expects lower full-year core profit as delivery delays bite
Nov 26, 2024
(Reuters) - British luxury carmaker Aston Martin on Tuesday forecast its annual core profit to fall short of 2023 levels as delivery delays in the ultra-exclusive Valiant models drag its margins. The company expects its 2024 adjusted EBITDA to be in the range of 270 million pounds to 280 million pounds ($338.55 million - $351.09 million) compared to 305.9 million...
Over 800 European financial groups deal with firms linked to Israeli settlements, NGOs say
Over 800 European financial groups deal with firms linked to Israeli settlements, NGOs say
Nov 26, 2024
* Israeli settlements expand by record amount * Report analyses financial stakes, loans by European companies * Growing number of financial institutions involved * Some financial actors are also divesting, report says By Emma Farge GENEVA, Nov 26 (Reuters) - A growing number of European financial institutions have a business relationship with companies with ties to Israeli settlements, according to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved